Literature DB >> 29906407

Crosstalk between the immune system and neural pathways in interstitial cystitis/bladder pain syndrome.

Kevin Duh1,2, Michael G Funaro1,2, William DeGouveia1,2, Sonia Bahlani3,4, Dominic Pappas1,2, Souhel Najjar5, Inna Tabansky6,7, Robert Moldwin3,4,7, Joel N H Stern1,2,5,7.   

Abstract

Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a condition causing intense pelvic pain and urinary symptoms. While it is thought to affect millions of people and significantly impair quality of life, difficulty with diagnosis and a lack of reliably effective treatment options leave much progress to be made in managing this condition. We describe what is currently known about the immunological and neurological basis of this disease, focusing on the interactions between the immune and nervous system. Evidence for immune involvement in IC/BPS comes from its high co-occurrence with known autoimmune diseases, altered cytokine profiles, and immune cell infiltration in patients. These cytokines have the ability to cross-talk with the nervous system via NGF signaling, resulting in hyper-sensitization of pain receptors, causing them to release substance P and creating a positive feedback loop of neuroinflammation. While it seems that the crosstalk between the immune and nervous system in IC is understood, much of the information comes from studying other diseases or from animal models, and it remains to be confirmed in patients with the disease. Identifying biomarkers and confirming the mechanism of IC/BPS are ultimately important for selecting drug targets and for improving the lives of patients with this disease.

Entities:  

Mesh:

Year:  2018        PMID: 29906407

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  8 in total

1.  TRPV4 blockade reduces voiding frequency, ATP release, and pelvic sensitivity in mice with chronic urothelial overexpression of NGF.

Authors:  Beatrice M Girard; Susan E Campbell; Megan Perkins; Harrison Hsiang; Katharine Tooke; Carolyn Drescher; Grant W Hennig; Thomas J Heppner; Mark T Nelson; Margaret A Vizzard
Journal:  Am J Physiol Renal Physiol       Date:  2019-10-21

2.  Integrating single-cell RNA sequencing with spatial transcriptomics reveals immune landscape for interstitial cystitis.

Authors:  Liao Peng; Xi Jin; Bo-Ya Li; Xiao Zeng; Bang-Hua Liao; Tao Jin; Jia-Wei Chen; Xiao-Shuai Gao; Wei Wang; Qing He; Guo Chen; Li-Na Gong; Hong Shen; Kun-Jie Wang; Hong Li; De-Yi Luo
Journal:  Signal Transduct Target Ther       Date:  2022-05-20

3.  Comparative effectiveness and safety of intravesical instillation treatment of interstitial cystitis/bladder pain syndrome: a systematic review and network meta-analysis of randomized controlled trials.

Authors:  Shengzhuo Liu; Chi Zhang; Liao Peng; Yiping Lu; Deyi Luo
Journal:  Int Urogynecol J       Date:  2020-09-04       Impact factor: 2.894

4.  Proteomic analysis of bladder biopsies from interstitial cystitis/bladder pain syndrome patients with and without Hunner's lesions reveals differences in expression of inflammatory and structural proteins.

Authors:  Elijah P Ward; Sarah N Bartolone; Michael B Chancellor; Kenneth M Peters; Laura E Lamb
Journal:  BMC Urol       Date:  2020-11-07       Impact factor: 2.264

5.  A nomogram for bladder pain syndrome/interstitial cystitis based on netrin-1.

Authors:  Xiaojie Ang; Yufeng Jiang; Zongqiang Cai; Qi Zhou; Miao Li; Bin Zhang; Weiguo Chen; Li-Hua Chen; Xi Zhang
Journal:  Int Urol Nephrol       Date:  2021-12-13       Impact factor: 2.370

6.  Immune cell profiles of patients with interstitial cystitis/bladder pain syndrome.

Authors:  Robert M Moldwin; Vishaan Nursey; Oksana Yaskiv; Siddhartha Dalvi; Eric J Macdonald; Michael Funaro; Chengliang Zhang; William DeGouveia; Marina Ruzimovsky; Horacio R Rilo; Edmund J Miller; Souhel Najjar; Inna Tabansky; Joel N H Stern
Journal:  J Transl Med       Date:  2022-02-21       Impact factor: 5.531

7.  Usefulness of Urinary Biomarkers for Assessing Bladder Condition and Histopathology in Patients with Interstitial Cystitis/Bladder Pain Syndrome.

Authors:  Yuan-Hong Jiang; Jia-Fong Jhang; Yuan-Hsiang Hsu; Hann-Chorng Kuo
Journal:  Int J Mol Sci       Date:  2022-10-10       Impact factor: 6.208

8.  Anesthetic Bladder Capacity is a Clinical Biomarker for Interstitial Cystitis/Bladder Pain Syndrome Subtypes.

Authors:  Andre Plair; Robert J Evans; Carl D Langefeld; Catherine A Matthews; Gopal Badlani; Stephen J Walker
Journal:  Urology       Date:  2021-07-22       Impact factor: 2.649

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.